SIREN : 919802496
SPFPL PHARMACIE DE L'ANSE is a French company founded 3 years ago, specialized in the sector Gestion de fonds. Based in KOUROU (97310), this company of category PME shows in 2025 a revenue of 90 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 90 000 € | 90 000 € | 67 500 € |
| Net income | 131 845 € | 133 226 € | 33 043 € |
| EBITDA | 83 652 € | 84 409 € | 50 734 € |
| Net margin | 146.5% | 148.0% | 49.0% |
In 2025, SPFPL PHARMACIE DE L'ANSE achieves revenue of 90 k€. Over the period 2023-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +15.5%. Slight decline of 0% vs 2024. After deducting consumption (0 €), gross margin stands at 90 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 84 k€, representing 92.9% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 132 k€, i.e. 146.5% of revenue. This profit can be retained or distributed to shareholders.
90 000 €
90 000 €
83 652 €
83 652 €
131 845 €
92.9%
The debt ratio (= Financial debt / Equity x 100) stands at 268%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 27%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 6.1 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 146.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
268.23%
27.036%
146.494%
6.085
In 2025, the debt ratio of SPFPL PHARMACIE DE L'ANSE (268.23) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of SPFPL PHARMACIE DE L'ANSE (27.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of SPFPL PHARMACIE DE L'ANSE (6.08) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 4967.49. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 21.1x. Operating income very largely covers interest expenses: high safety margin.
4967.492
21.111
In 2025, the liquidity ratio of SPFPL PHARMACIE DE L'ANSE (4967.49) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2025, the interest coverage of SPFPL PHARMACIE DE L'ANSE (21.1x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 204 days. Excellent situation: suppliers finance 204 days of the operating cycle (retail model). Overall, WCR represents 806 days of revenue, i.e. 202 k€ to permanently finance. Over 2023-2025, WCR increased by +225%, requiring additional financing.
201 546 €
0 j
204 j
0 j
806 j
Indicative estimate only : the number of comparable transactions in this sector is limited (40 transactions). This range of 50 615€ to 353 793€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 40 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SPFPL PHARMACIE DE L'ANSE with other companies in the same sector:
The revenue of SPFPL PHARMACIE DE L'ANSE in 2025 is 90 k€.
Yes, SPFPL PHARMACIE DE L'ANSE generated a net profit of 132 k€ in 2025.
The headquarters of SPFPL PHARMACIE DE L'ANSE is located in KOUROU (97310), in the department Guyane.
The tax return of SPFPL PHARMACIE DE L'ANSE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SPFPL PHARMACIE DE L'ANSE operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.